EANS-News: Intercell Recognized by U.S. Department of Defense for Development of Japanese Encephalitis Vaccine, IXIARO®

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Vienna (Austria)/Washington (USA), May 25, 2010 (euro adhoc) - Intercell AG
(VSE: ICLL) has been honored in a ceremony at the Pentagon today for the
company´s role in the development of Japanese encephalitis vaccine, IXIARO®. The
Commanding General, United States Army Medical Research and Materiel Command
(USAMRMC), the Acting Secretary of Defense for Health Affairs (HA) and Gerd
Zettlmeissl, chief executive officer of Intercell, commented on the excellent
collaborative efforts between the Department of Defense (DoD) and Intercell that
lead to the development and subsequent commercialization for IXIARO. Senior DoD
officials also expressed their appreciation to Intercell for making a
next-generation JE vaccine available for use by Service members. As a result of
this public-private effort, military personnel, dependants, and civilian
travelers will be protected against the serious and growing risk of disease
caused by the JE virus when deployed or traveling to many countries of the
world.

Gerd Zettlmeissl commented, "We are extremely honored to be recognized by the
DoD for our collaborative research and development efforts. Special recognition
is given to our colleagues at Walter Reed Army Institute of Research (WRAIR) who
initiated this JE vaccine project in the mid 1990s and contributed to numerous
aspects of the development program up to licensure."

IXIARO was developed under a Collaborative Research and Development Agreement
(CRADA) with WRAIR and approved in March 2009 by the U.S. Food and Drug
Administration for the prevention of Japanese Encephalitis. Intercell currently
distributes and markets IXIARO to the U.S. military, with Novartis Vaccines USA
marketing and distributing the vaccine to the private market in the U.S.

Japanese Encephalitis is a mosquito-borne infection that strikes approximately
50,000 persons per year and is most common in developing countries in Asia,
including India and China.

Further inquiry note:
Intercell AG
Lucia Malfent
Vice President, Global Head Corporate Communications
Tel. +43 1 20620-1303
[email protected]
end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Intercell AG
Campus Vienna Biocenter 3
A-1030 Wien
phone: +43 1 20620-0
FAX: +43 1 20620-800
mail: [email protected]
WWW: www.intercell.com
sector: Biotechnology
ISIN: AT0000612601
indexes: ATX Prime, ATX
stockmarkets: official market: Wien
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | CNE

print